KPV vs SS-31 (Elamipretide)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

KPV

KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the tanning or other melanocortin effects.

Full details →

SS-31 (Elamipretide)

SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.

Full details →

Side-by-Side Comparison

AspectKPVSS-31 (Elamipretide)
MechanismInhibits NF-κB activation and reduces inflammatory cytokine production. Enters cells and directly modulates inflammatory signaling without requiring melanocortin receptors.Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency.
Typical DosageOral/sublingual: 200-500mcg 1-3 times daily. Topical formulations for localized inflammation. Also used in enemas for gut inflammation.Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily.
AdministrationCan be taken orally, sublingually, or as suppositories/enemas for gut inflammation. Topical use for skin conditions. Stable orally unlike most peptides.Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions.
Side EffectsGenerally very well-tolerated. Minimal systemic effects due to targeted anti-inflammatory action.Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache.
Best For

What They Have in Common

Both KPV and SS-31 (Elamipretide) are commonly used for:

Key Differences

Unique to KPV:

Unique to SS-31 (Elamipretide):

Ready to Learn More?